Coronary Stents Market by Product Type (Bare Metal Stents, Bioresorbable Vascular Scaffold, Drug Eluting Stents), Material (Cobalt Chromium, Nitinol, Stainless Steel), Coating, Application, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Coronary Stents Market was valued at USD 9.31 billion in 2024 and is projected to grow to USD 10.20 billion in 2025, with a CAGR of 10.78%, reaching USD 21.14 billion by 2032.
Introduction to the contemporary coronary stent landscape emphasizing clinical imperatives, regulatory rigor, and operational priorities driving device adoption
The introduction establishes the clinical and commercial context of coronary stents against a backdrop of rapid technological refinement, evolving guideline priorities, and shifting payer dynamics. Contemporary cardiology practice increasingly emphasizes personalized device selection that aligns stent design with lesion pathology, patient comorbidities, and long-term antiplatelet management, prompting device developers to pursue incremental performance improvements alongside demonstrable safety outcomes. As a result, interventional cardiology teams and healthcare systems are recalibrating procurement frameworks to prioritize devices that reduce procedural complexity, shorten recovery trajectories, and minimize downstream adverse events.
In addition to clinical drivers, regulatory expectations and health economic scrutiny are shaping how new stent technologies navigate adoption. Regulatory pathways place weight on comparative safety data and post-market surveillance, while health systems demand clear evidence of value over existing alternatives. This combination influences investment priorities across manufacturers and investors, with success contingent on rigorous clinical programs, targeted real-world evidence generation, and effective education for operators and payers. Finally, procedural settings are diversifying as ambulatory surgical centers expand capabilities and hospitals reorganize cardiac services to improve throughput and reduce costs, requiring manufacturers to address a broader set of operational requirements when positioning their stent portfolios.
How clinical imaging, materials innovation, evidence generation, and supply chain resilience are converging to transform coronary stent competition and adoption
Transformative shifts in the coronary stent landscape are rooted in converging technological, clinical, and delivery-model trends that are reshaping decision-making at the point of care. Advances in polymer science, thin-strut metallurgy, and surface engineering have enabled stents to balance deliverability with durable safety, while a renewed focus on bioresorbable scaffolding and polymer-free drug elution seeks to optimize healing responses and reduce long-term device footprint. Simultaneously, precision imaging modalities and intravascular physiology tools have migrated from research centers to routine practice, improving lesion assessment and enabling more selective device use.
Commercially, vendors are adapting to a multi-channel distribution reality and refining value propositions for diverse end users, from high-volume cardiac centers to ambulatory surgical settings. This shift is complemented by growing emphasis on post-market registries and pragmatic trials that supply payers and clinicians with granular data on performance across representative patient cohorts. Moreover, supply chain resilience and manufacturing agility have become strategic differentiators after recent global disruptions, prompting near-shoring and flexible production strategies. Collectively, these trends accelerate iterative device innovation and recalibrate competitive dynamics, privileging organizations that synchronize clinical evidence generation with scalable commercialization and robust stakeholder engagement.
Assessing the cumulative operational, procurement, and strategic consequences of United States tariff measures introduced in 2025 on coronary stent supply chains
The imposition of new trade measures and tariffs in 2025 has introduced an added layer of complexity for manufacturers and healthcare purchasers, influencing sourcing strategies, pricing negotiations, and inventory practices across the supply chain. Organizations with vertically integrated manufacturing footprints or diversified supplier bases were better equipped to mitigate immediate cost impacts, while others faced pressure to re-evaluate vendor agreements and absorb incremental expenses. Importantly, the tariffs prompted many firms to accelerate manufacturing localization and strategic partnerships to ensure continuity of supply and to limit exposure to import-related volatility.
Hospitals and procurement entities responded by intensifying total-cost-of-ownership evaluations and seeking contractual protections that buffer against tariff-induced price swings. In parallel, procurement teams increased emphasis on long-term supplier relationships and demand forecasting to smooth supply fluctuations. Regulatory and reimbursement stakeholders also monitored cost trajectories closely, recognizing that sustained price pressure could influence formulary decisions and procedural volumes. In synthesis, the cumulative tariff effects catalyzed structural responses across the ecosystem: supply chain reconfiguration, renegotiated commercial terms, and a sharpened focus on manufacturing agility and cost transparency that continue to inform strategic planning.
Granular segmentation analysis revealing how product architecture, material science, coating strategies, clinical application, end-user setting, and distribution channels determine strategic priorities
Key segmentation insights illuminate how product, material, coating, application, end-user, and distribution distinctions intersect to shape clinical positioning and commercial strategy. Based on Product Type, the market is studied across Bare Metal Stents, Bioresorbable Vascular Scaffold, and Drug Eluting Stents; within Drug Eluting Stents, further segmentation includes Polymer Coated and Polymer Free variants, and Polymer Coated devices are further categorized into Everolimus Eluting, Sirolimus Eluting, and Zotarolimus Eluting constructs. These product distinctions drive distinct R&D priorities and messaging: bare metal options retain relevance for specific acute interventions and cost-sensitive settings, bioresorbable scaffolds continue to attract investigational focus for temporary scaffolding benefits, and drug eluting variants command attention for chronic disease management and restenosis reduction.
Based on Material, stents crafted from Cobalt Chromium, Nitinol, and Stainless Steel exhibit trade-offs between radial strength, flexibility, and imaging compatibility that inform operator preference and lesion-specific selection. Based on Coating, the market is studied across Polymer Coated, Polymer Free, and Uncoated devices, with coating strategy influencing drug release kinetics and healing profiles. Based on Application, devices are categorized for Acute Myocardial Infarction and Chronic Coronary Artery Disease, reflecting differing procedural urgencies and antiplatelet strategies. Based on End User, adoption contexts span Ambulatory Surgical Centers, Cardiac Centers, and Hospitals, each with unique procurement cycles and clinical throughput expectations. Based on Distribution Channel, market dynamics incorporate Direct Sales, Distributors, and Online routes, which affect pricing, training, and post-sale support models. Understanding these cross-cutting segments enables focused clinical trial design, tailored marketing, and alignment of service and training offerings to accelerate uptake in priority clinical niches.
Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape regulatory access, procurement behavior, and commercialization pathways for coronary stents
Regional insights underscore differing clinical practices, regulatory environments, and commercial models that materially influence product strategy and market access planning. In the Americas, variation in reimbursement frameworks and a mature interventional cardiology infrastructure promote rapid uptake of incremental innovations when supported by robust outcomes data and economic justification. Clinician networks and high procedural volumes provide fertile ground for adoption, but payers increasingly require real-world evidence to justify premium positioning.
In Europe, Middle East & Africa, heterogeneous regulatory regimes and diverse healthcare funding models produce varied entry pathways and adoption speeds; centralized procurement in some jurisdictions contrasts with privatized markets in others, requiring tailored value messages. Local manufacturing and regulatory alignment can accelerate access where cost containment strategies predominate. In the Asia-Pacific region, high-growth healthcare investments, expanding procedural capacity, and government-driven modernization programs are creating demand for devices that balance performance with cost effectiveness. Rapid urbanization and increasing prevalence of coronary disease drive procedural demand, while local production and strategic partnerships remain critical to navigate regulatory complexity and price sensitivity. Collectively, these regional dynamics necessitate differentiated commercialization plans, localized evidence generation, and adaptive supply chain strategies.
How market leaders and challengers align clinical evidence, manufacturing scale, and strategic partnerships to differentiate coronary stent propositions and commercial footholds
Company-level insights focus on how leading and emerging players are aligning portfolios, clinical programs, and commercialization approaches to compete effectively. Established manufacturers emphasize incremental material and coating enhancements, expanded service offerings, and stronger clinician engagement through investigator-initiated studies and training programs. They leverage scale advantages to support reimbursement negotiations and to fund long-term safety studies required by regulators and payers. Conversely, challenger companies target niche clinical needs with differentiated technologies such as polymer-free drug delivery or novel bioresorbable scaffolds while pursuing focused real-world evidence to validate claims and accelerate adoption among early-adopter centers.
Strategic collaborations, licensing arrangements, and targeted acquisitions are common tactics to acquire complementary capabilities quickly, particularly in imaging-enabled devices, proprietary coatings, and regional distribution networks. Companies that combine robust clinical evidence with scalable manufacturing and flexible commercial models tend to achieve stronger alignment with hospital procurement priorities. Finally, an increasing number of firms invest in digital support platforms and procedural guidance tools to enhance operator experience and to create ecosystem lock-in that extends beyond the device itself, supporting higher lifetime value per customer and deeper clinical integration.
Practical strategic imperatives to unify clinical evidence generation, manufacturing agility, and market-specific commercialization to accelerate adoption and mitigate risk
Actionable recommendations for industry leaders emphasize prioritizing integrated strategies that link clinical evidence, supply chain resilience, and market-tailored commercialization. First, align clinical development with payer evidence needs by designing pragmatic, outcomes-focused registries that complement randomized data and demonstrate value across representative patient populations. Second, invest in flexible manufacturing footprints and qualified secondary suppliers to reduce tariff and geopolitical exposure while improving lead times and responsiveness to demand shifts. Third, tailor product portfolios to regional clinical practices and procurement models, ensuring that device attributes and pricing reflect local hospital workflows and payer expectations.
Additionally, enhance operator training and post-sale support through digital education platforms and hybrid training models that blend remote simulation with hands-on proctoring to accelerate safe adoption. Pursue selective partnerships and licensing deals to access complementary materials or distribution channels that shorten time to market and broaden clinical reach. Finally, refine commercial models to reflect end-user diversity: develop distinct value propositions for ambulatory centers, high-volume cardiac centers, and hospitals, and tailor distribution approaches-direct, distributor, or online-to match customer preferences and scale. By executing these recommendations, industry leaders can translate technical innovation into durable clinical adoption and sustainable commercial performance.
Methodological framework combining primary clinician engagement, rigorous secondary evidence synthesis, and comparative device and supply chain analytics to validate strategic insights
The research methodology integrates multi-modal evidence generation to ensure robustness, transparency, and applicability to commercial decision-making. Primary data collection included structured interviews with interventional cardiologists, procurement executives, and clinical trial leads to capture frontline perspectives on device selection criteria, procedural workflow constraints, and evidence expectations. Secondary research synthesized regulatory guidance documents, peer-reviewed clinical studies, device registries, and white papers to create a consistent evidentiary foundation that contextualizes innovation trajectories and safety signals.
Analytical techniques combined qualitative thematic analysis with comparative device profiling to evaluate feature trade-offs and competitive positioning. Supply chain analysis assessed manufacturing footprints, supplier concentration, and logistical vulnerability to identify operational levers and resilience opportunities. Regional and end-user segmentation was informed by demographic disease burden, procedural capacity, and procurement modalities to ensure relevance across markets. Throughout, methodological rigor was maintained by triangulating findings across independent sources and validating key insights with clinical and commercial experts to reduce bias and increase practical relevance for decision-makers.
Strategic synthesis emphasizing integrated clinical, operational, and commercial capabilities as the decisive factors for future success in coronary stent adoption
The conclusion synthesizes the principal narrative: coronary stent innovation now advances at the intersection of material science, targeted drug delivery, and pragmatic evidence generation, while commercialization success depends on manufacturing resilience, regional adaptability, and payer-aligned value demonstration. Clinicians increasingly demand devices that reconcile deliverability with long-term safety, and payers require real-world performance data that justify premium positioning. Consequently, companies that integrate clinical, operational, and commercial capabilities will be best placed to translate technical advances into sustainable adoption.
Looking forward, success will hinge on the ability to couple differentiated device attributes with disciplined evidence strategies and flexible go-to-market models. Organizations that proactively address tariff and supply chain exposures, invest in training and digital support, and pursue partnerships to fill capability gaps will reduce execution risk and accelerate market penetration. Ultimately, a balanced focus on patient-centered outcomes, operational excellence, and tailored commercial execution will determine which players lead the next phase of growth in coronary stent care pathways.
Please Note: PDF & Excel + Online Access - 1 Year
Introduction to the contemporary coronary stent landscape emphasizing clinical imperatives, regulatory rigor, and operational priorities driving device adoption
The introduction establishes the clinical and commercial context of coronary stents against a backdrop of rapid technological refinement, evolving guideline priorities, and shifting payer dynamics. Contemporary cardiology practice increasingly emphasizes personalized device selection that aligns stent design with lesion pathology, patient comorbidities, and long-term antiplatelet management, prompting device developers to pursue incremental performance improvements alongside demonstrable safety outcomes. As a result, interventional cardiology teams and healthcare systems are recalibrating procurement frameworks to prioritize devices that reduce procedural complexity, shorten recovery trajectories, and minimize downstream adverse events.
In addition to clinical drivers, regulatory expectations and health economic scrutiny are shaping how new stent technologies navigate adoption. Regulatory pathways place weight on comparative safety data and post-market surveillance, while health systems demand clear evidence of value over existing alternatives. This combination influences investment priorities across manufacturers and investors, with success contingent on rigorous clinical programs, targeted real-world evidence generation, and effective education for operators and payers. Finally, procedural settings are diversifying as ambulatory surgical centers expand capabilities and hospitals reorganize cardiac services to improve throughput and reduce costs, requiring manufacturers to address a broader set of operational requirements when positioning their stent portfolios.
How clinical imaging, materials innovation, evidence generation, and supply chain resilience are converging to transform coronary stent competition and adoption
Transformative shifts in the coronary stent landscape are rooted in converging technological, clinical, and delivery-model trends that are reshaping decision-making at the point of care. Advances in polymer science, thin-strut metallurgy, and surface engineering have enabled stents to balance deliverability with durable safety, while a renewed focus on bioresorbable scaffolding and polymer-free drug elution seeks to optimize healing responses and reduce long-term device footprint. Simultaneously, precision imaging modalities and intravascular physiology tools have migrated from research centers to routine practice, improving lesion assessment and enabling more selective device use.
Commercially, vendors are adapting to a multi-channel distribution reality and refining value propositions for diverse end users, from high-volume cardiac centers to ambulatory surgical settings. This shift is complemented by growing emphasis on post-market registries and pragmatic trials that supply payers and clinicians with granular data on performance across representative patient cohorts. Moreover, supply chain resilience and manufacturing agility have become strategic differentiators after recent global disruptions, prompting near-shoring and flexible production strategies. Collectively, these trends accelerate iterative device innovation and recalibrate competitive dynamics, privileging organizations that synchronize clinical evidence generation with scalable commercialization and robust stakeholder engagement.
Assessing the cumulative operational, procurement, and strategic consequences of United States tariff measures introduced in 2025 on coronary stent supply chains
The imposition of new trade measures and tariffs in 2025 has introduced an added layer of complexity for manufacturers and healthcare purchasers, influencing sourcing strategies, pricing negotiations, and inventory practices across the supply chain. Organizations with vertically integrated manufacturing footprints or diversified supplier bases were better equipped to mitigate immediate cost impacts, while others faced pressure to re-evaluate vendor agreements and absorb incremental expenses. Importantly, the tariffs prompted many firms to accelerate manufacturing localization and strategic partnerships to ensure continuity of supply and to limit exposure to import-related volatility.
Hospitals and procurement entities responded by intensifying total-cost-of-ownership evaluations and seeking contractual protections that buffer against tariff-induced price swings. In parallel, procurement teams increased emphasis on long-term supplier relationships and demand forecasting to smooth supply fluctuations. Regulatory and reimbursement stakeholders also monitored cost trajectories closely, recognizing that sustained price pressure could influence formulary decisions and procedural volumes. In synthesis, the cumulative tariff effects catalyzed structural responses across the ecosystem: supply chain reconfiguration, renegotiated commercial terms, and a sharpened focus on manufacturing agility and cost transparency that continue to inform strategic planning.
Granular segmentation analysis revealing how product architecture, material science, coating strategies, clinical application, end-user setting, and distribution channels determine strategic priorities
Key segmentation insights illuminate how product, material, coating, application, end-user, and distribution distinctions intersect to shape clinical positioning and commercial strategy. Based on Product Type, the market is studied across Bare Metal Stents, Bioresorbable Vascular Scaffold, and Drug Eluting Stents; within Drug Eluting Stents, further segmentation includes Polymer Coated and Polymer Free variants, and Polymer Coated devices are further categorized into Everolimus Eluting, Sirolimus Eluting, and Zotarolimus Eluting constructs. These product distinctions drive distinct R&D priorities and messaging: bare metal options retain relevance for specific acute interventions and cost-sensitive settings, bioresorbable scaffolds continue to attract investigational focus for temporary scaffolding benefits, and drug eluting variants command attention for chronic disease management and restenosis reduction.
Based on Material, stents crafted from Cobalt Chromium, Nitinol, and Stainless Steel exhibit trade-offs between radial strength, flexibility, and imaging compatibility that inform operator preference and lesion-specific selection. Based on Coating, the market is studied across Polymer Coated, Polymer Free, and Uncoated devices, with coating strategy influencing drug release kinetics and healing profiles. Based on Application, devices are categorized for Acute Myocardial Infarction and Chronic Coronary Artery Disease, reflecting differing procedural urgencies and antiplatelet strategies. Based on End User, adoption contexts span Ambulatory Surgical Centers, Cardiac Centers, and Hospitals, each with unique procurement cycles and clinical throughput expectations. Based on Distribution Channel, market dynamics incorporate Direct Sales, Distributors, and Online routes, which affect pricing, training, and post-sale support models. Understanding these cross-cutting segments enables focused clinical trial design, tailored marketing, and alignment of service and training offerings to accelerate uptake in priority clinical niches.
Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape regulatory access, procurement behavior, and commercialization pathways for coronary stents
Regional insights underscore differing clinical practices, regulatory environments, and commercial models that materially influence product strategy and market access planning. In the Americas, variation in reimbursement frameworks and a mature interventional cardiology infrastructure promote rapid uptake of incremental innovations when supported by robust outcomes data and economic justification. Clinician networks and high procedural volumes provide fertile ground for adoption, but payers increasingly require real-world evidence to justify premium positioning.
In Europe, Middle East & Africa, heterogeneous regulatory regimes and diverse healthcare funding models produce varied entry pathways and adoption speeds; centralized procurement in some jurisdictions contrasts with privatized markets in others, requiring tailored value messages. Local manufacturing and regulatory alignment can accelerate access where cost containment strategies predominate. In the Asia-Pacific region, high-growth healthcare investments, expanding procedural capacity, and government-driven modernization programs are creating demand for devices that balance performance with cost effectiveness. Rapid urbanization and increasing prevalence of coronary disease drive procedural demand, while local production and strategic partnerships remain critical to navigate regulatory complexity and price sensitivity. Collectively, these regional dynamics necessitate differentiated commercialization plans, localized evidence generation, and adaptive supply chain strategies.
How market leaders and challengers align clinical evidence, manufacturing scale, and strategic partnerships to differentiate coronary stent propositions and commercial footholds
Company-level insights focus on how leading and emerging players are aligning portfolios, clinical programs, and commercialization approaches to compete effectively. Established manufacturers emphasize incremental material and coating enhancements, expanded service offerings, and stronger clinician engagement through investigator-initiated studies and training programs. They leverage scale advantages to support reimbursement negotiations and to fund long-term safety studies required by regulators and payers. Conversely, challenger companies target niche clinical needs with differentiated technologies such as polymer-free drug delivery or novel bioresorbable scaffolds while pursuing focused real-world evidence to validate claims and accelerate adoption among early-adopter centers.
Strategic collaborations, licensing arrangements, and targeted acquisitions are common tactics to acquire complementary capabilities quickly, particularly in imaging-enabled devices, proprietary coatings, and regional distribution networks. Companies that combine robust clinical evidence with scalable manufacturing and flexible commercial models tend to achieve stronger alignment with hospital procurement priorities. Finally, an increasing number of firms invest in digital support platforms and procedural guidance tools to enhance operator experience and to create ecosystem lock-in that extends beyond the device itself, supporting higher lifetime value per customer and deeper clinical integration.
Practical strategic imperatives to unify clinical evidence generation, manufacturing agility, and market-specific commercialization to accelerate adoption and mitigate risk
Actionable recommendations for industry leaders emphasize prioritizing integrated strategies that link clinical evidence, supply chain resilience, and market-tailored commercialization. First, align clinical development with payer evidence needs by designing pragmatic, outcomes-focused registries that complement randomized data and demonstrate value across representative patient populations. Second, invest in flexible manufacturing footprints and qualified secondary suppliers to reduce tariff and geopolitical exposure while improving lead times and responsiveness to demand shifts. Third, tailor product portfolios to regional clinical practices and procurement models, ensuring that device attributes and pricing reflect local hospital workflows and payer expectations.
Additionally, enhance operator training and post-sale support through digital education platforms and hybrid training models that blend remote simulation with hands-on proctoring to accelerate safe adoption. Pursue selective partnerships and licensing deals to access complementary materials or distribution channels that shorten time to market and broaden clinical reach. Finally, refine commercial models to reflect end-user diversity: develop distinct value propositions for ambulatory centers, high-volume cardiac centers, and hospitals, and tailor distribution approaches-direct, distributor, or online-to match customer preferences and scale. By executing these recommendations, industry leaders can translate technical innovation into durable clinical adoption and sustainable commercial performance.
Methodological framework combining primary clinician engagement, rigorous secondary evidence synthesis, and comparative device and supply chain analytics to validate strategic insights
The research methodology integrates multi-modal evidence generation to ensure robustness, transparency, and applicability to commercial decision-making. Primary data collection included structured interviews with interventional cardiologists, procurement executives, and clinical trial leads to capture frontline perspectives on device selection criteria, procedural workflow constraints, and evidence expectations. Secondary research synthesized regulatory guidance documents, peer-reviewed clinical studies, device registries, and white papers to create a consistent evidentiary foundation that contextualizes innovation trajectories and safety signals.
Analytical techniques combined qualitative thematic analysis with comparative device profiling to evaluate feature trade-offs and competitive positioning. Supply chain analysis assessed manufacturing footprints, supplier concentration, and logistical vulnerability to identify operational levers and resilience opportunities. Regional and end-user segmentation was informed by demographic disease burden, procedural capacity, and procurement modalities to ensure relevance across markets. Throughout, methodological rigor was maintained by triangulating findings across independent sources and validating key insights with clinical and commercial experts to reduce bias and increase practical relevance for decision-makers.
Strategic synthesis emphasizing integrated clinical, operational, and commercial capabilities as the decisive factors for future success in coronary stent adoption
The conclusion synthesizes the principal narrative: coronary stent innovation now advances at the intersection of material science, targeted drug delivery, and pragmatic evidence generation, while commercialization success depends on manufacturing resilience, regional adaptability, and payer-aligned value demonstration. Clinicians increasingly demand devices that reconcile deliverability with long-term safety, and payers require real-world performance data that justify premium positioning. Consequently, companies that integrate clinical, operational, and commercial capabilities will be best placed to translate technical advances into sustainable adoption.
Looking forward, success will hinge on the ability to couple differentiated device attributes with disciplined evidence strategies and flexible go-to-market models. Organizations that proactively address tariff and supply chain exposures, invest in training and digital support, and pursue partnerships to fill capability gaps will reduce execution risk and accelerate market penetration. Ultimately, a balanced focus on patient-centered outcomes, operational excellence, and tailored commercial execution will determine which players lead the next phase of growth in coronary stent care pathways.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of bioresorbable magnesium stents reducing long-term thrombosis risk
- 5.2. Integration of drug-eluting coating innovations targeting complex coronary lesions
- 5.3. Expansion of robotic-assisted percutaneous coronary interventions improving precision
- 5.4. Growing demand for dual therapy stents addressing restenosis and healing simultaneously
- 5.5. Advancements in patient-specific stent sizing aided by 3D imaging and AI algorithms
- 5.6. Market penetration of thin strut cobalt chromium stents enhancing deliverability
- 5.7. Regulatory approvals shaping opportunities for next-generation biodegradable polymer stents
- 5.8. Impact of China and India expanding public health programs on coronary stent consumption
- 5.9. Evolution of remote monitoring and digital health platforms for post-stenting patient follow-up
- 5.10. Competitive dynamics from low-cost stent manufacturers influencing pricing strategies
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Coronary Stents Market, by Product Type
- 8.1. Bare Metal Stents
- 8.2. Bioresorbable Vascular Scaffold
- 8.3. Drug Eluting Stents
- 8.3.1. Polymer Coated
- 8.3.1.1. Everolimus Eluting
- 8.3.1.2. Sirolimus Eluting
- 8.3.1.3. Zotarolimus Eluting
- 8.3.2. Polymer Free
- 9. Coronary Stents Market, by Material
- 9.1. Cobalt Chromium
- 9.2. Nitinol
- 9.3. Stainless Steel
- 10. Coronary Stents Market, by Coating
- 10.1. Polymer Coated
- 10.2. Polymer Free
- 10.3. Uncoated
- 11. Coronary Stents Market, by Application
- 11.1. Acute Myocardial Infarction
- 11.2. Chronic Coronary Artery Disease
- 12. Coronary Stents Market, by End User
- 12.1. Ambulatory Surgical Centers
- 12.2. Cardiac Centers
- 12.3. Hospitals
- 13. Coronary Stents Market, by Distribution Channel
- 13.1. Direct Sales
- 13.2. Distributors
- 13.3. Online
- 14. Coronary Stents Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Coronary Stents Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Coronary Stents Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Abbott Laboratories
- 17.3.2. Alvimedica Medical Technologies Inc.
- 17.3.3. amg International GmbH
- 17.3.4. Asahi Intecc Co., Ltd.
- 17.3.5. B. Braun Melsungen AG
- 17.3.6. Balton Sp. z o.o.
- 17.3.7. Biosensors International Group, Ltd.
- 17.3.8. Biotronik SE & Co. KG
- 17.3.9. Boston Scientific Corporation
- 17.3.10. Cook Medical Inc.
- 17.3.11. Cordis Corporation
- 17.3.12. Elixir Medical Corporation
- 17.3.13. Eurocor GmbH
- 17.3.14. Hexacath S.A.
- 17.3.15. InspireMD, Inc.
- 17.3.16. Lepu Medical Technology (Beijing) Co., Ltd.
- 17.3.17. Medtronic plc
- 17.3.18. Meril Life Sciences Pvt. Ltd.
- 17.3.19. MicroPort Scientific Corporation
- 17.3.20. OrbusNeich Medical Group
- 17.3.21. REVA Medical, Inc.
- 17.3.22. Sahajanand Medical Technologies Pvt. Ltd.
- 17.3.23. Stentys S.A.
- 17.3.24. Terumo Corporation
- 17.3.25. Translumina GmbH
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
